Skip to main content

CAPITAL FUND MANAGEMENT S.A.

Position in HALO — Halozyme Therapeutics, Inc.

CIK 1323645 PARIS, I0

Position in HALO

as of Mar 31, 2026 · filed May 14, 2026
Position Value
$11,270,050
-$3,507,616 QoQ
Shares Held
174,378
-20.6% QoQ
Ownership
0.147%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Jun 2023
9 quarters on record
Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Common Shares in HALO Over Time

Shares Held

Position Value (USD)

Derivatives in HALO

reported options exposure · as of Mar 31, 2024
CallValue
$504,432
CallShares
12,400
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CAPITAL FUND MANAGEMENT S.A. holds $292,594,996 across 34 Biotechnology names. HALO ranks #6 (3.9% of the industry book) .

# Ticker Company Shares Value (USD) Open
6 HALO
Halozyme Therapeutics, Inc.
This page
174,378 $11,270,050

All Filings in HALO

Export CSV
14 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $11,270,050 174,378
2025-12-31 $14,777,666 219,579
2025-09-30 $15,602,424 212,741
2025-06-30 $5,613,530 107,911
2024-12-31 $1,118,084 23,386
2024-03-31 $2,422,575 59,552
2024-03-31 $504,432 12,400
2023-12-31 $1,515,396 41,001
2023-12-31 $543,312 14,700
2023-12-31 $687,456 18,600
2023-09-30 $1,608,220 42,100
2023-09-30 $580,640 15,200
2023-09-30 $542,134 14,192
2023-06-30 $1,893,675 52,500